Disposition of flurbiprofen in man: influence of stereochemistry and age

References

• ADVENIER, C., Roux, A., GOBERT, C., MASSINS, P., VAROQUAUX, 0. and FLOUVAT, B., 1983, Pharmacokinetics of ketoprofen in the elderly. British Journal of Clinical Pharmacology, 16, 65–70.
   Google Scholar
• BLOUIN, R., CHAUDHARY, I., NISHIHARA, K. and Cox, S., 1993, The effects of liver and renal disease on stereoselective serum binding of flurbiprofen. British Journal of Clinical Pharmacology, 35, 62–64.
   PubMed Web of Science ®Google Scholar
• BRUNE, K., BECK, W. S., GEISSLINGER, G., MENZEL-SOGLOWEK, S., PESKAR, B. M. and PESKAR, B. A., 1991, Aspirin-like drugs block pain independently of prostaglandin synthesis inhibition. Experientia, 47, 257–261.
   Google Scholar
• BURITOVA, J. and BESSON, J.-M., 1998, Peripheral and/or central effects of racemic-, S(+)- and R( — )-flurbiprofen on inflammatory nociceptive processes: a c-FOS protein study in the rat spinal cord. British Journal of Pharmacology, 125, 87–101.
   Google Scholar
• CARABAZA, A., CABRE, F., ROTLLAN, E., GómEz, M., GUTIERREZ, M., GARCIA, L. and MAULEON, D., 1996, Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflam-matory drugs. Journal of Clinical Pharmacology, 36, 505–512.
   Google Scholar
• CEFALI, E. A., POYNOR, W. J., SICA, D. and Cox, S., 1991, Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. Journal of Clinical Pharmacology, 31, 808–814.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM, G., DODD, T. R. P., GRANT, D. J., McMurtuo, M. E. J. and RICHARDS, R. M. E., 1997, Drug related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age and Ageing, 26, 375–382.
   Google Scholar
• DENNIS, M. J., FRENCH, P. C., CROME, P., BABIKE, M., SHILLINGFORD, J. and HOPKINS, R., 1985, Pharmacokinetic profile of controlled release ketoprofen in elderly patients. British Journal of Clinical Pharmacology, 20, 567–573.
   PubMed Web of Science ®Google Scholar
• DODHIA, V., PATEL, N., HUTT, A. J. and FORBES, B., 2002, Stereoselective and metabolite-mediated antiproliferative effects of non-steroidal anti-inflammatory drugs. Journal of Pharmacy and Pharmacology, 54 (Suppl.), S–100.
   Google Scholar
• FRYE, R. F., TRACY, T. S., HUTZLER, J. M., KORZEKWA, K. R., CANNON, Y., PAULI, M., HUANG, S.-M. and BRANCH, R. A., 2000, Flurbiprofen as a selective in vivo probe of CYP2C9 activity. Pharmaceutical Research, 67, 109.
   Google Scholar
• GEISSLINGER, G. and SCHAIBLE, H.-G., 1996, New insight into the site and mode of antinociceptive action of flurbiprofen enantiomers. Journal of Clinical Pharmacology, 36, 513–520.
   Google Scholar
• GEISSLINGER, G., LöTscH, J., MENZEL, S., KOBAL, G. and BRUNE, K., 1994, Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. British Journal of Clinical Pharmacology, 37, 392–394.
   Google Scholar
• GEISSLINGER, G., MUTH-SELBACH, U., COSTE, 0., VETTER, G., SCHRQDTER, A., SCHAIBLE, H.-G., BRUNE, K. and TEGEDER, I., 2000, Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: a microdialysis study. Journal of Neurochemistry, 74, 2094–2100.
   Google Scholar
• HAMDOUNE, M., MOUNIE, J., MAGDALOU, J., MASMOUDI, T., GOUDONNET, H. and ESCOUSSE, A., 1995, Characterization of the in vitro glucuronidation of flurbiprofen enantiomers. Drug Metabolism and Disposition, 23, 343–348.
   PubMed Web of Science ®Google Scholar
• HAMDY, R. C., BIRD, A., LE GALLEZ, P., HILL, J. and HIND, I. D., 1990, A multiple dose pharmacokinetic and tolerance study of once daily dose 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. European Journal of Clinical Pharmacology, 39, 267–270.
   PubMed Web of Science ®Google Scholar
• HAMDY, R. C., NASAR, A., JAMES, M., HIND, I. D. and MARCHANT, B., 1980, Pharmacokinetics of flurbiprofen in elderly subjects. British Journal of Clinical Practise, 9 (Suppl.), 6–9.
   Google Scholar
• HAMMAN, M. A., THOMPSON, G. A. and HALL, S. D., 1997, Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochemical Pharmacology, 54, 33–41.
   PubMed Web of Science ®Google Scholar
• HAMMERLEIN, A., DERENDORF, H. and LOWENTHAL, D. T., 1998, Pharmacokinetic and pharmacody-namic changes in the elderly — clinical implications. Clinical Pharmacokinetics, 35, 49–64.
   PubMed Web of Science ®Google Scholar
• HUTZLER, J. M., FRYE, R. F. and TRACY, T. S., 2000, Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. Journal of Chromatography B, 749, 119–125.
   PubMed Web of Science ®Google Scholar
• IN'T VELD, B. A., RUITENBERG, A., HOFMAN, A., LAANNER, L. J., VAN DUIJI, C. M., STIJNEN, T., BRETELER, M. M. B. and STRICKER, B. H. C., 2001, Nonsteroidal antiinfiammatory drugs and the risk of Alzheimer's disease. New England Journal of Medicine, 345, 1515–1521.
   PubMed Web of Science ®Google Scholar
• JAMALI, F., BERRY, B. W., TEHRANI, M. R. and RUSSELL, A. S., 1988, Stereoselective pharmacokinetics of flurbiprofen in humans and rats. Journal of Pharmaceutical Sciences, 77, 666–669.
   PubMed Web of Science ®Google Scholar
• JAMALI, F., COLLINS, D. S., BERRY, B. W., MOLDER, S., CHEUNG, R., MuCoLL, K. and CHEUNG, H., 1991, Comparative bioavailability of two flurbiprofen products: stereospecific versus conventional approach. Biopharmaceutics and Drug Disposition, 12, 435–455.
   PubMed Web of Science ®Google Scholar
• JERUSSI, T. P., CAUBET, J.-F., MCCRAY, J. E. and HANDLEY, D. A., 1998, Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)-ketoprofen, (R)-flurbiprofen, racemic ketoprofen and paracetamol: a randomized, single-blind, placebo-controlled trial. Journal of Clinical Pharmacology, 38, 19S–24S.
   Google Scholar
• KEAN, W. F., ANTAL, E. J., GRACE, E. M., CAUVIER, H., RISCHKE, J. and BUCHANAN, W. W., 1992, The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. Journal of Clinical Pharmacology, 32, 41–48.
   PubMed Web of Science ®Google Scholar
• KEEGAN, P. and LOUGHMAN, B. E., 2001, Early clinical trials of chemopreventive and biologic agents: designs, populations and end points. Urology, 57 (Suppl 4A), 216–219.
   Google Scholar
• KNADLER, M. P. and HALL, S. D., 1990, Stereoselective arylpropionyl-CoA thioester formation in vitro. Chirality, 2, 67–73.
   PubMed Web of Science ®Google Scholar
• KNADLER, M. P. and HALL, S. D., 1991, Stereoselective hydrolysis of flurbiprofen conjugates. Drug Metabolism and Disposition, 19, 280–282.
   PubMed Web of Science ®Google Scholar
• KNADLER, M. P., BRATER, D. C. and HALL, S. D., 1989, Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status. Journal of Pharmacology and Experimental Therapeutics, 249, 378–385.
   PubMed Web of Science ®Google Scholar
• KNADLER, M. P., BRATER, D. C. and HALL, S. D., 1992a, Stereoselective disposition of flurbiprofen in normal volunteers. British Journal of Clinical Pharmacology, 33, 369–375.
   PubMed Web of Science ®Google Scholar
• KNADLER, M. P., BRATER, D. C. and HALL, S. D., 1992b, Stereoselective disposition of flurbiprofen in uraemic patients. British Journal of Clinical Pharmacology, 33, 377–383.
   PubMed Web of Science ®Google Scholar
• KNIFinvicxi, R. D., WILLIAMS, K. M. and DAY, R. 0., 1989, Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs I. In vitro studies of ibuprofen and flurbiprofen. Biochemical Pharmacology, 38, 4389–4395.
   Google Scholar
• MAHMUD, T., SOMASUNDARAM, S., SIGTHORSSON, G., SIMPSON, R. J., RAFI, S., FOSTER, R., TAVARES, I. A., ROSETH, A., HUTT, A. J., JACOB, M., PACY, J., SCOTT, D. L., WRIGGLESWORTH, J. M. and BJARNSON, I., 1998, Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat. Gut, 43, 775–782.
   PubMed Web of Science ®Google Scholar
• MCCRACKEN, J. D., WECHTER, W. J., LIM, Y., CHASE, R. L., KANTOCI, D., MURRAY, E. D., QUIGGLE, D. D. and MINEYAMA, Y., 1996, Antiproliferative effects of the enantiomers of flurbiprofen. Journal of Clinical Pharmacology, 36, 540–545.
   PubMed Web of Science ®Google Scholar
• MENZEL-SOGLOWEK, S., GEISSLINGER, G., BECK, W. S. and BRUNE, K., 1992, Variability of inversion of (R)-flurbiprofen in different species. Journal of Pharmaceutical Sciences, 81, 888–891.
   Google Scholar
• MOONEY, H., ROBERTS, R. and COOKSLEY, W., 1985, Alterations in the liver with ageing. Gastroenterology, 14, 757–771.
   Web of Science ®Google Scholar
• MORIHARA, T., CFR3, T., UBEDA, 0., BEECH, W. and COLE, G. M., 2002, Selective inhibition of A1342 production by NSAID R-enantiomers. Journal of Neurochemistry, 83, 1009–1012.
   Google Scholar
• OELKERS, R., NEUPERT, W., WILLIAMS, K. M., BRUNE, K. and GEISSLINGER, G., 1997, Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. British Journal of Clinical Pharmacology, 43, 145–153.
   PubMed Web of Science ®Google Scholar
• PAGE, J. and HENRY, D., 2000, Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An under recognized public health problem. Archives of Internal Medicine, 160, 777–784.
   PubMed Web of Science ®Google Scholar
• PATEL, B. K., VALENTOVA, J. and HUTT, A. J., 2002, Chromatographic separation and enantiomeric resolution of flurbiprofen and its major metabolites. Chromatographia, 55, 135–142.
   Web of Science ®Google Scholar
• PATEL, B. K., VALENTOVA, J. and HUTT, A. J., 2003, Stereospecific analysis of flurbiprofen and its major metabolites in plasma and urine by chiral-phase liquid chromatography. Chromatographia, 57, 7–18.
   Web of Science ®Google Scholar
• PORUBEK, D. J., SANINS, S. M., STEPHENS, J. R., GRILLO, M. P., KAISER, D. G., HALSTEAD, G. W., ADAMS, W. J. and BAILLIE, T. A., 1991, Metabolic chiral inversion of flurbiprofen-CoA in vitro. Biochemical Pharmacology, 42, R1—R4.
   Web of Science ®Google Scholar
• RISDALL, P. C., ADAMS, S. S., CRAMPTON, E. L. and MARCHANT, B., 1978, The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica, 8, 691–704.
   PubMed Web of Science ®Google Scholar
• ROWLAND, M. and TOZER, T. N., 1995, Metabolite kinetics. In Clinical Pharmacokinetics (Philadelphia: Lea & Febiger), pp. 367–394.
   Google Scholar
• RUDY, A. C., KNIGHT, P. M., BRATER, D. C. and HALL, S. D., 1995, Enantioselective disposition of ibuprofen in elderly persons with or without renal impairment. Journal of Pharmacology and Experimental Therapeutics, 273, 88–93.
   PubMed Web of Science ®Google Scholar
• SCHMUCKER, D. L., WOODHOUSE, K. W., WANG, R. K., WYNNE, H., JAMES, 0. F., McMANus, M. and KREMERS, P., 1990, Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clinical Pharmacology and Therapeutics, 48, 365–374.
   Google Scholar
• SMALL, R. E., Cox, S. R. and ADAMS, W. R., 1990, Influence of H2 receptor antagonists on the disposition of the enantiomers of flurbiprofen. Journal of Clinical Pharmacology, 30, 660–664.
   PubMed Web of Science ®Google Scholar
• SOTANIEMI, E. A., ARRANTO, A. J., PELKONEN, 0. and PASANEN, M., 1997, Age and cytochrome P450-linked drug metabolism in humans. An analysis of 226 subjects with equal histopathologic conditions. Clinical Pharmacology and Therapeutics, 61, 331–339.
   Google Scholar
• SURI, A., GRUNDY, B. L. and DERENDORF, H., 1997, Pharmacokinetics and pharmacodynamics of the enantiomers of ibuprofen and flurbiprofen after oral administration. International Journal of Clinical Pharmacology and Therapeutics, 35, 1–8.
   PubMed Web of Science ®Google Scholar
• SZPUNAR, G. J., ALBERT, K. S., BOLE, G. G., DREYFUS, J. N., LOCKWOOD, G. F. and WAGNER, J. F., 1987, Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. Biopharmaceutics and Drug Disposition, 8, 273–283.
   PubMed Web of Science ®Google Scholar
• TAN, S. C., PATEL, B. K., JACKSON, S. H. D., SWIFT, C. G. and HUTT, A. J., 2003, Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers. British Journal of Clinical Pharmacology, 55, 579–587.
   Google Scholar
• TEGEDER, I., NIEDERBERGER, E., ISRAR, E., GeHRING, H., BRUNE, K., EUCHENHOFER, C., GRöscx, S. and GEISSLINGER, G., 2001a, Inhibition of NF-KB and AP-1 activation by R- and S-flurbiprofen. FASEB Journal, 15, 2–4.
   Google Scholar
• TEGEDER, I., PFEILSCHIFTER, J. and GEISSLINGER, G., 2001b, Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB Journal, 15, 2057–2072.
   PubMed Web of Science ®Google Scholar
• TRACY, T. S., MARRA, C., WRIGHTON, S. A., GONZALEZ, F. J. and KORZEKWA, K. R., 1996, Studies of flurbiprofen 4'-hydroxylation — additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochemical Pharmacology, 52, 1305–1309.
   PubMed Web of Science ®Google Scholar
• TRACY, T. S., ROSENBLUTH, B. W., WRIGHTON, S. A., GONZALEZ, F. J. and KORZEKWA, K. R., 1995, Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Biochemical Pharmacology, 49, 1269–1275.
   PubMed Web of Science ®Google Scholar
• TRAMER, M. R., MOORE, R. A., REYNOLDS, D. J. M. and McQuAY, H. J., 2000, Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain, 85, 169–182.
   Google Scholar
• WALLACE, S. M. and VERBEECK, R. K., 1987, Plasma protein binding of drugs in the elderly. Clinical Pharmacokinetics, 12, 41–72.
   PubMed Web of Science ®Google Scholar
• WECHTER, W. J., BIGORNIA, A. E., MURRAY, E. D., LEVINE, B. H. and YOUNG, J. W., 1993, Rac-Flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality, 5, 492–494.
   PubMed Web of Science ®Google Scholar
• WECHTER, W. J., LEIPOLD, D. D., MURRAY, E. D., QUIGGLE, D. D., MCCRACKEN, J. D., BARRIOS, R. S. and GREENBERG, N. M., 2000b, E-7869 (R-Flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Research, 60, 2203–2208.
   PubMed Web of Science ®Google Scholar
• WECHTER, W. J., MURRAY, E. D., KANTOCI, D., QUIGGLE, D. D., LEIPOLD, D. D., GIBSON, K. M. and MCCRACKEN, J. D., 2000a, Treatment and survival study in the C57BL/6J-APCmini+ (MIN) mouse with R-flurbiprofen. Life Sciences, 66, 745–753.
   PubMed Web of Science ®Google Scholar
• WEGGEN, S., ERIKSEN, J. L., DAS, P., SAGI, S. A., WANG, R., PIETRZIK, C. U., FINDLAY, K. A., SMITH, T. E., MURPHY, M. P., BUTLER, T., KANG, D. E., MARQUEZ-STERLING, N., GOLDE, T. E. and Koo, E. H., 2001, A subset of NSAIDs lower amyloidogenic A1342 independently of cyclooxygenase activity. Nature, 414, 212–216.
   Google Scholar
• WOLFE, M. M., LICHTENSTEIN, D. R. and SINGH, G., 1999, Gastrointestinal toxicity of NSAIDs. New England Journal of Medicine, 340, 1888–1899.
   PubMed Web of Science ®Google Scholar
• WOODHOUSE, K. W. and WYNNE, H., 1987, The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clinical Pharmacokinetics, 12, 111–122.
   PubMed Web of Science ®Google Scholar
• YOUNG, M. A., AARONS, L. and TOON, S., 1991, The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 31, 102–104.
   PubMed Web of Science ®Google Scholar